Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report

被引:12
作者
Santamato, Andrea [1 ]
Panza, Francesco [2 ,3 ]
Di Venere, Daniela [4 ]
Solfrizzi, Vincenzo [3 ]
Frisardi, Vincenza [3 ]
Ranieri, Maurizio [5 ]
Fiore, Pietro [1 ]
机构
[1] Univ Foggia, Dept Phys Med & Rehabil OORR, I-71100 Foggia, Italy
[2] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Geriatr Unit & Gerontol Geriatr Res Lab, Foggia, Italy
[3] Univ Bari, Ctr Aging Brain, Dept Geriatr, Memory Unit, Bari, Italy
[4] Univ Bari, Odontostomatol & Chirurg Dept, Bari, Italy
[5] Univ Bari, Dept Neurol & Psychiat Sci, Bari, Italy
关键词
EES: bruxism; Neck pain; Botulinum toxin type A;
D O I
10.1016/j.jcm.2010.04.004
中图分类号
R49 [康复医学];
学科分类号
100215 [康复医学与理疗学];
摘要
Objective: This case report describes a patient with nocturnal bruxism and related neck pain treated with botulinum toxin type A (BTX-A). Clinical Features: The patient was a 27-year-old man with nocturnal bruxism and difficulty in active mouth opening and chewing and neck pain at rest. His numeric pain score was 7 of 10. Surface electromyography of the temporalis and masseter muscles showed typical signs of hyperactivity, characterized by compound muscle action potential amplitude alterations. Intervention and Outcome: After clinical evaluation, he was treated with BTX-A to reduce masseter and temporalis muscle hyperactivity. After 3 days of treatment with BTX-A, with each masseter muscle injected with a dose of about 40 mouse units with a dilution of 1 mL and with temporal muscle bilaterally injected with 25 mouse units with the same dilution, a decrease in bruxism symptoms was reported. Neck pain also decreased after the first treatment (visual analog scale of 2/10) and then resolved completely. After 4 weeks, electromyography showed the reduction of muscle hyperactivity with a decrease in the amplitude of the motor action potential. The same reduction in signs and symptoms was still present at assessment 3 months posttreatment. Conclusion: These findings suggest that BTX-A may be a therapeutic option for the treatment of bruxism and related disorders. (C) 2010 National University of Health Sciences.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 48 条
[1]
AASM, 2005, INT CLASSIFICATION S
[2]
*AC PROSTH, 2005, J PROSTHET DENT, V94, P1
[3]
Attanasio R, 1997, Dent Clin North Am, V41, P309
[4]
Babadag M, 2004, QUINTESSENCE INT, V35, P811
[5]
Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations [J].
Bhidayasiri, R ;
Cardoso, F ;
Truong, DD .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 :21-29
[6]
Bowley John F., 1993, Journal of Orofacial Pain, V7, P378
[7]
Carlsson GE, 2003, J OROFAC PAIN, V17, P50
[8]
Chikhani L., 2003, Annales de Readaptation et de Medecine Physique, V46, P333, DOI 10.1016/S0168-6054(03)00115-6
[9]
The relationship of bruxism with craniofacial pain and symptoms from the masticatory system in the adult population [J].
Ciancaglini, R ;
Gherlone, EF ;
Radaelli, G .
JOURNAL OF ORAL REHABILITATION, 2001, 28 (09) :842-848
[10]
Clark Glenn T, 2007, Dent Clin North Am, V51, P225, DOI 10.1016/j.cden.2006.09.002